OmniAbOABI
OABI
About: OmniAb Inc offers therapeutic antibody discovery technologies. It focuses on enabling the rapid development of therapeutics by pushing the frontiers of drug discovery technologies. Its technology platform is designed to enable the efficient discovery of high-quality, fully human antibodies for a wide range of diseases. The heart of the OmniAb technology platform is the Biological Intelligence of its proprietary transgenic animals, including OmniRat, OmniMouse, and OmniChicken, that have been genetically modified to generate antibodies with human sequences which are naturally optimized through in vivo affinity maturation.
Employees: 114
0
Funds holding %
of 7,425 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
243% more call options, than puts
Call options by funds: $120K | Put options by funds: $35K
12% more first-time investments, than exits
New positions opened: 19 | Existing positions closed: 17
9% more repeat investments, than reductions
Existing positions increased: 50 | Existing positions reduced: 46
0% more funds holding
Funds holding: 163 [Q3] → 163 (+0) [Q4]
14.99% less ownership
Funds ownership: 67.52% [Q3] → 52.53% (-14.99%) [Q4]
33% less capital invested
Capital invested by funds: $334M [Q3] → $225M (-$110M) [Q4]
50% less funds holding in top 10
Funds holding in top 10: 2 [Q3] → 1 (-1) [Q4]
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$4
135%
upside
Avg. target
$7
312%
upside
High target
$11
547%
upside
3 analyst ratings
3 positive
100%
0 neutral
0%
0 negative
0%
RBC Capital Conor McNamara 17% 1-year accuracy 7 / 41 met price target | 135%upside $4 | Outperform Maintained | 27 Mar 2025 |
Benchmark Robert Wasserman 31% 1-year accuracy 13 / 42 met price target | 253%upside $6 | Buy Maintained | 20 Mar 2025 |
HC Wainwright & Co. Joseph Pantginis 21% 1-year accuracy 89 / 416 met price target | 547%upside $11 | Buy Reiterated | 19 Mar 2025 |
Financial journalist opinion
Neutral
Business Wire
1 week ago
OmniAb Announces Two New Appointments to its Board of Directors
EMERYVILLE, Calif.--(BUSINESS WIRE)--OmniAb, Inc. (NASDAQ: OABI) today announced the appointments of Philip J. Gotwals, Ph.D., and Steve Crouse to its Board of Directors. OmniAb also announced the departure of Director Sarah Boyce, who is stepping down following nearly six years of service during a period of key strategic acquisitions and the significant expansion of the scope and size of OmniAb's partnership base. These Board changes are effective immediately and increase the number of Directo.
Neutral
Seeking Alpha
1 month ago
OmniAb, Inc. (OABI) Q4 2024 Earnings Call Transcript
OmniAb, Inc. (NASDAQ:OABI ) Q4 2024 Earnings Conference Call March 18, 2025 4:30 PM ET Company Participants Kurt Gustafson - Chief Financial Officer Matt Foehr - President & Chief Executive Officer Conference Call Participants Joe Pantginis - H.C. Wainwright Kripa Devarakonda - Truist Securities Operator Good afternoon and welcome to OmniAb Inc's Fourth Quarter and Full Year 2024 Financial Results and Business Update Conference call.
Negative
Zacks Investment Research
1 month ago
OmniAb, Inc. (OABI) Reports Q4 Loss, Tops Revenue Estimates
OmniAb, Inc. (OABI) came out with a quarterly loss of $0.12 per share versus the Zacks Consensus Estimate of a loss of $0.13. This compares to loss of $0.14 per share a year ago.
Neutral
Business Wire
1 month ago
OmniAb Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights
EMERYVILLE, Calif.--(BUSINESS WIRE)--OmniAb, Inc. (NASDAQ: OABI) today reported financial results for the three and 12 months ended December 31, 2024, and provided operating and partner program updates. “2024 was a remarkable year featuring double-digit percentage growth in the number of both active partners and programs. Clinical-stage programs advanced well, and we launched new technologies and enhancements that strengthened our platform and expanded our reach,” said Matt Foehr, Chief Executi.
Neutral
Business Wire
2 months ago
OmniAb to Report Fourth Quarter 2024 Financial Results on March 18
EMERYVILLE, Calif.--(BUSINESS WIRE)--OmniAb, Inc. (NASDAQ: OABI) will report financial results for the three and 12 months ended December 31, 2024 after the close of the U.S. financial markets on Tuesday, March 18, 2025 and will hold a conference call that same day beginning at 4:30 p.m. Eastern time. Conference Call and Webcast Information What: OmniAb conference call to discuss fourth quarter financial results and business updates Date: Tuesday, March 18, 2025 Time: 4:30 p.m.
Neutral
Business Wire
2 months ago
OmniAb to Participate in Two Investor Conferences in March
EMERYVILLE, Calif.--(BUSINESS WIRE)--OmniAb, Inc. (NASDAQ: OABI) today announced that management will be participating in two investor conferences during the month of March. TD Cowen 45th Annual Health Care Conference, March 3-5 at the Boston Marriott Copley Place. Management will be presenting a corporate overview on Tuesday, March 4th at 2:30 p.m. Eastern time and will be holding one-on-one meetings with investors. 2025 Leerink Partners Global Healthcare Conference, March 9-12 at the W Hotel.
Neutral
PRNewsWire
2 months ago
Kuehn Law Encourages Investors of OmniAb, Inc. to Contact Law Firm
NEW YORK , Jan. 31, 2025 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of OmniAb, Inc. (NASDAQ: OABI) breached their fiduciary duties to shareholders. The investigation concerns potential self-dealing.
Neutral
Business Wire
4 months ago
OmniAb Technologies Featured in Two Presentations at the 2024 Antibody Engineering & Therapeutics Conference
EMERYVILLE, Calif.--(BUSINESS WIRE)--OmniAb, Inc. (NASDAQ: OABI) today announced that two presentations featuring the Company's technologies were delivered at the 2024 Antibody Engineering & Therapeutics Conference (AETC) underway in San Diego. In a presentation titled “Building Multispecifics from in vivo Derived Antibody Domains and Alternative Scaffolds,” Yasmina Abdiche, Ph.D., Vice President of Exploratory Research, provided an overview of building multispecifics ranging from tradition.
Neutral
Seeking Alpha
5 months ago
OmniAb, Inc. (OABI) Q3 2024 Earnings Call Transcript
OmniAb, Inc. (NASDAQ:OABI ) Q3 2024 Earnings Conference Call November 12, 2024 4:30 PM ET Company Participants Kurt Gustafson - Chief Financial Officer Matt Foehr - President & Chief Executive Officer Conference Call Participants Stephen Willey - Stifel Alex Xenakis - Truist Securities Jacqueline Kisa - TD Cowen Conor McNamara - RBC Capital Markets Operator Good afternoon, and welcome to OmniAb, Inc. Third Quarter 2024 Financial Results and Business Update Conference Call. At this time, all participants are in a listen-only mode.
Negative
Zacks Investment Research
5 months ago
OmniAb, Inc. (OABI) Reports Q3 Loss, Lags Revenue Estimates
OmniAb, Inc. (OABI) came out with a quarterly loss of $0.16 per share versus the Zacks Consensus Estimate of a loss of $0.14. This compares to loss of $0.16 per share a year ago.
Charts implemented using Lightweight Charts™